CCM
VIR icon

Catalio Capital Management’s Vir Biotechnology VIR Stock Holding History

Catalio Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-388,303
Closed -$1.96M – 47
2025
Q2 		$1.96M Sell
388,303
-223,305
-37% -$1.2M 0.41% 29
2025
Q1 		$3.96M Buy
+611,608
New +$5.44M 0.96% 24

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Catalio Capital Management's VIR Position: Q3 2025 in Review

Catalio Capital Management sold out of Vir Biotechnology (VIR) in Q3 2025, closing a stake of 388,303 shares — an estimated $1.96M sold.

Catalio Capital Management first reported a position in VIR in Q1 2025 and held it in 2 quarters. The position peaked at $3.96M in Q1 2025. 213 funds tracked by Wall St. Rank hold VIR as of Q3 2025.

  • Catalio Capital Management reported no remaining Vir Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Catalio Capital Management sold 388,303 Vir Biotechnology shares in Q3 2025, an estimated $1.96M.
  • Catalio Capital Management first reported a position in Vir Biotechnology in Q1 2025 and held it in 2 quarters.
  • Catalio Capital Management's Vir Biotechnology position peaked at $3.96M in Q1 2025.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2025.

Based on Catalio Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.